CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Forty Seven, Inc. is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Forty Seven, Inc.
1490 Obrien Dr
Suite A
Phone: (650) 352-4150p:650 352-4150 Menlo Park, CA  94025-1499  United States Fax: (302) 655-5049f:302 655-5049
This company was Merged or Acquired on 4/7/2020.
This company ceased filing statements with the SEC on 4/17/2020.
This company is no longer actively traded on any major stock exchange.
This is a Subsidiary, click here for the Parent Company
Business Summary
Forty Seven, Inc. is clinical-stage immuno-oncology company. The Company is focused on developing novel checkpoint therapies to activate macrophages in the fight against cancer. The Company’s lead product candidate, 5F9, is a humanized IgG4 subclass monoclonal antibody against CD47 that is designed to interfere with recognition of CD47 by the SIRPa receptor on macrophages. The Company’s another product FSI-189, is an antibody that binds to SIRPa and initiate Phase I solid tumor trials for FSI-189. The Company is investigating 5F9 in multiple Phase I and Phase II trials in various cancers including acute myeloid leukemia (AML), non-Hodgkin's lymphoma (NHL) and colorectal carcinoma (CRC), and ovarian cancer, as both a monotherapy and in combination with other therapies, such as rituximab and cetuximab. In addition to the 5F9, which is an antibody that binds to CD47 blocking its binding to SIRPa.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/201912/31/2019YesYes---

Industries
SIC Code Description
8731 Commercial physical and biological research
8071 Medical laboratories

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
President, Chief Executive Officer, Director Mark A.McCamish 67 5/1/2017 5/1/2017
Chief Financial Officer Ann D.Rhoads 53 3/1/2018 3/1/2018
Chief Business Officer Craig S.Gibbs 56
6 additional Officers and Directors records available in full report.

Business Names
Business Name
FORTY SEVEN INC
FTSV

General Information
Number of Employees: 68 (As of 12/31/2019)
Outstanding Shares: 48,156,251 (As of 3/16/2020)
Shareholders: 47
Stock Exchange: NASD
Federal Tax Id: 474065674
Fax Number: (302) 655-5049
Email Address: info@fortyseveninc.com


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, July 21, 2023